Sunil Kumar Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sunil Kumar Singh has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Kumar
Department of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India
3 shared publications - Shruti Singh
Department of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India
3 shared publications - Alok Kumar
Department of Pharmacology, All India Institute of Medical Sciences, Patna, India
2 shared publications - Pramod Kumar Manjhi
Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India
2 shared publications - Shuvasree Payra
Department of Pharmacology, All India Institute of Medical Sciences, Patna, India
2 shared publications - Vikas Maharshi
Department of Pharmacology, All India Institute of Medical Sciences, Patna, 801507, India
2 shared publications
Latest Publications
- Open Access
- 24 June 2025
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 14 (4) , 565-582
Addressing cardio-metabolic risks in type 2 diabetes: evidence-based insights on efpeglenatide
Type 2 diabetes (T2D) is a chronic metabolic disorder linked to significant complications, including cardiovascular disease (CVD) and chronic kidney disease (CKD). Efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has emerged as a promising therapy for addressing glycemic control, weight management, and cardio metabolic risks. A systematic review of randomized controlled trials (RCTs) was conducted using PRISMA guidelines. Searches in PubMed, Google Scholar, and Science Direct identified studies on efpeglenatide impact on T2D outcomes. Data on efficacy, safety, dose-response, and combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors were extracted and analyzed. Out of 843 studies screened, 10 were included. The AMPLITUDE-O trial showed a 27% reduction in major adverse cardiovascular events (MACEs) (hazard ratio [HR]: 0.73, p=0.007) and significant renal benefits (HR: 0.68, p<0.001). Phase 2 trials demonstrated HbA1c reductions (0.6%-1.2%) and weight loss (up to 7.5%). Gastrointestinal side effects were common but mild to moderate, with no major safety concerns. Sub-analyses indicated that combining efpeglenatide with SGLT2 inhibitors did not diminish its efficacy, suggesting potential synergy in reducing cardio metabolic risks. Efpeglenatide demonstrates robust efficacy in glycemic control, weight loss, and reducing cardiovascular and renal risks, with a tolerable safety profile. Its long-acting properties and compatibility with SGLT2 inhibitors support its use in comprehensive, individualized T2D management. Further research is warranted to refine dosing strategies and evaluate long-term outcomes in diverse patient populations.
- 24 June 2025
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 14 (4) , 565-582
Open AccessAddressing cardio-metabolic risks in type 2 diabetes: evidence-based insights on efpeglenatide
Type 2 diabetes (T2D) is a chronic metabolic disorder linked to significant complications, including cardiovascular disease (CVD) and chronic kidney disease (CKD). Efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has emerged as a promising therapy for addressing glycemic control, weight management, and cardio metabolic risks. A systematic review of randomized controlled trials (RCTs) was conducted using PRISMA guidelines. Searches in PubMed, Google Scholar, and Science Direct identified studies on efpeglenatide impact on T2D outcomes. Data on efficacy, safety, dose-response, and combination with sodium-glucose cotransporter-2 (SGLT2) inhibitors were extracted and analyzed. Out of 843 studies screened, 10 were included. The AMPLITUDE-O trial showed a 27% reduction in major adverse cardiovascular events (MACEs) (hazard ratio [HR]: 0.73, p=0.007) and significant renal benefits (HR: 0.68, p<0.001). Phase 2 trials demonstrated HbA1c reductions (0.6%-1.2%) and weight loss (up to 7.5%). Gastrointestinal side effects were common but mild to moderate, with no major safety concerns. Sub-analyses indicated that combining efpeglenatide with SGLT2 inhibitors did not diminish its efficacy, suggesting potential synergy in reducing cardio metabolic risks. Efpeglenatide demonstrates robust efficacy in glycemic control, weight loss, and reducing cardiovascular and renal risks, with a tolerable safety profile. Its long-acting properties and compatibility with SGLT2 inhibitors support its use in comprehensive, individualized T2D management. Further research is warranted to refine dosing strategies and evaluate long-term outcomes in diverse patient populations.
- 20 September 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (9) , 667-685
Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis
Background and Objectives Dolutegravir has been used as a first-line anti-human immunodeficiency virus drug because of its better efficacy compared with other counterpart medicines. However, making a unanimous decision on its use during pregnancy has become difficult for stakeholders following congenital anomalies reported with its use. The objective of this systematic review and meta-analysis was to study the risk of congenital anomalies in newborns exposed to dolutegravir-based-regimens compared with those exposed to non-dolutegravir-based regimens during the antenatal period. Methods An extensive literature search was performed in MEDLINE (through PubMed), EMBASE, Cochrane Database of Systematic Reviews, Google Scholar, and ClinicalTrials.gov until 30 November, 2023. Studies reporting data on congenital anomalies following antenatal use of dolutegravir were included. Risk of bias for randomized controlled trials, non-randomized controlled trials, and observational studies was assessed using RoB2, ROBINS-I, and ROBINS-E tools, respectively. A meta-analysis was performed in ‘RevMan 5.4.1’ using a random-effects model. Heterogeneity was assessed by the ‘Q’ statistic and I2 value. A sensitivity analysis was performed for higher heterogeneity/high-risk studies. The study protocol was registered in PROSPERO [CRD42023446374] a priori. Results Of 26 eligible studies, 12 (six randomized controlled trials and six observational studies with a pooled sample of 32,617) were included in a meta-analysis and 14 in a qualitative synthesis only. The meta-analysis does not show a statistically significant difference in the risk of congenital anomalies between newborns exposed antenatally to dolutegravir-based regimen(s) and those exposed to non-dolutegravir-based regimens [risk ratio 1.10; 95% confidence interval 0.79–1.53; p = 0.59]. Heterogeneity was moderate (I2 = 47%). Pooled results for randomized controlled trials and observational studies separately and the sensitivity analysis for heterogeneity provided similar results. Conclusions The risk of congenital anomalies was not significantly different between dolutegravir-based regimens and non-dolutegravir-based-regimens in newborns exposed during their antenatal period.
- 20 September 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (9) , 667-685
Risk of Congenital Anomalies with Dolutegravir-Based Anti-retroviral Regimens: A Systematic Review and Meta-analysis
Background and Objectives Dolutegravir has been used as a first-line anti-human immunodeficiency virus drug because of its better efficacy compared with other counterpart medicines. However, making a unanimous decision on its use during pregnancy has become difficult for stakeholders following congenital anomalies reported with its use. The objective of this systematic review and meta-analysis was to study the risk of congenital anomalies in newborns exposed to dolutegravir-based-regimens compared with those exposed to non-dolutegravir-based regimens during the antenatal period. Methods An extensive literature search was performed in MEDLINE (through PubMed), EMBASE, Cochrane Database of Systematic Reviews, Google Scholar, and ClinicalTrials.gov until 30 November, 2023. Studies reporting data on congenital anomalies following antenatal use of dolutegravir were included. Risk of bias for randomized controlled trials, non-randomized controlled trials, and observational studies was assessed using RoB2, ROBINS-I, and ROBINS-E tools, respectively. A meta-analysis was performed in ‘RevMan 5.4.1’ using a random-effects model. Heterogeneity was assessed by the ‘Q’ statistic and I2 value. A sensitivity analysis was performed for higher heterogeneity/high-risk studies. The study protocol was registered in PROSPERO [CRD42023446374] a priori. Results Of 26 eligible studies, 12 (six randomized controlled trials and six observational studies with a pooled sample of 32,617) were included in a meta-analysis and 14 in a qualitative synthesis only. The meta-analysis does not show a statistically significant difference in the risk of congenital anomalies between newborns exposed antenatally to dolutegravir-based regimen(s) and those exposed to non-dolutegravir-based regimens [risk ratio 1.10; 95% confidence interval 0.79–1.53; p = 0.59]. Heterogeneity was moderate (I2 = 47%). Pooled results for randomized controlled trials and observational studies separately and the sensitivity analysis for heterogeneity provided similar results. Conclusions The risk of congenital anomalies was not significantly different between dolutegravir-based regimens and non-dolutegravir-based-regimens in newborns exposed during their antenatal period.
- 11 October 2023
- Published by Wiley in HIV Medicine
- Vol. 25 (3) , 322-331
HIV cure: Are we going to make history?
Background: At present, combination antiretroviral therapy (cART) is the mainstay for the treatment of people living with HIV/AIDS. cART can suppress the viral load to a minimal level; however, the possibility of the emergence of full‐blown AIDS is always there. In the latter part of the first decade of the 21st century, an HIV‐positive person received stem cell transplantation (SCT) for treatment of his haematological malignancy. The patient was able to achieve remission of the haematological condition as well as of HIV following SCT. Thorough investigations of various samples including blood and biopsy could not detect the virus in the person's body. The person was declared to be the first cured case of HIV.Literature search: Over the next decade, a few more similar cases were observed and have recently been declared cured of the infection. A comprehensive search was performed in PubMed, Cochrane library and Google Scholar. Four such additional cases were found in literature.Description & Discussion: These cases all share a common proposed mechanism for the HIV cure, that is, transplantation of stem cells from donors carrying a homozygous mutation in a gene encoding for CCR5 (receptor utilized by HIV for entry into the host cell), denoted as CCR5△32. This mutation makes the host immune cells devoid of CCR5, causing the host to acquire resistance against HIV. To the best of our knowledge, this is the first review to look at relevant and updated information of all cured cases of HIV as well as the related landmarks in history and discusses the underlying mechanism(s).
- 11 October 2023
- Published by Wiley in HIV Medicine
- Vol. 25 (3) , 322-331
HIV cure: Are we going to make history?
Background: At present, combination antiretroviral therapy (cART) is the mainstay for the treatment of people living with HIV/AIDS. cART can suppress the viral load to a minimal level; however, the possibility of the emergence of full‐blown AIDS is always there. In the latter part of the first decade of the 21st century, an HIV‐positive person received stem cell transplantation (SCT) for treatment of his haematological malignancy. The patient was able to achieve remission of the haematological condition as well as of HIV following SCT. Thorough investigations of various samples including blood and biopsy could not detect the virus in the person's body. The person was declared to be the first cured case of HIV.Literature search: Over the next decade, a few more similar cases were observed and have recently been declared cured of the infection. A comprehensive search was performed in PubMed, Cochrane library and Google Scholar. Four such additional cases were found in literature.Description & Discussion: These cases all share a common proposed mechanism for the HIV cure, that is, transplantation of stem cells from donors carrying a homozygous mutation in a gene encoding for CCR5 (receptor utilized by HIV for entry into the host cell), denoted as CCR5△32. This mutation makes the host immune cells devoid of CCR5, causing the host to acquire resistance against HIV. To the best of our knowledge, this is the first review to look at relevant and updated information of all cured cases of HIV as well as the related landmarks in history and discusses the underlying mechanism(s).
- 28 August 2023
- Published by Sciencedomain International in Journal of Advances in Medical and Pharmaceutical Sciences
- Vol. 25 (8) , 38-49
Assessment of the Cost Differences and Variability of Medicines for the Treatment of Heart Failure in India
- 28 August 2023
- Published by Sciencedomain International in Journal of Advances in Medical and Pharmaceutical Sciences
- Vol. 25 (8) , 38-49
Assessment of the Cost Differences and Variability of Medicines for the Treatment of Heart Failure in India
- Open Access
- 21 June 2021
- Published by Akshantala Enterprises Private Limited in Journal of Evolution of Medical and Dental Sciences
- Vol. 10 (25) , 1883-1888
A Study of Determinants of Obesity - Is Skipping Breakfast Meal a Risk Factor?
BACKGROUND Breakfast is an important meal since it refuels the body after long night fasting. Regular intake of breakfast must have favourable supply of both micronutrients and macronutrients to maintain a body mass index (BMI) in the normal range. Despite its importance, the rate of skipping breakfast is observed to be alarmingly increasing among medical students. Therefore, the present study was undertaken to understand the dietary patterns, and physical activity level, and analyse the association of skipping breakfast with obesity among medical students. METHODS A cross-sectional study was conducted among 174 medical undergraduate students aged between 18 and 23 years in a tertiary care teaching hospital from August 2019 to October 2019. A pretested, semi-structured, validated, self-administered questionnaire was used to assess the profile, physical activity, food consumption pattern, and perception about the importance of breakfast meal. Regression analysis was done. Odds ratio was calculated. RESULTS About 23.6 % and 27 % of the study participants were found to be overweight and obese respectively. Only 51.1 % of study participants were involved in physical activity. 17.2 % of medical students skipped their breakfast regularly and 71.6 % were aware that skipping breakfast would affect work efficacy and span of concentration. Age group of 22 – 23 years (OR: 19.5, 95 % CI; 2.08, 183.70) was significantly associated with obesity. Skipping breakfast (OR, 0.45, 95 % CI: 0.23, 0.90) was not found to be associated with obesity. CONCLUSIONS Our study found that more than one fourth participants were obese and one third were skipping breakfast daily or more than thrice a week. There was no association between obesity and skipping of breakfast meal. However, the importance of breakfast meal in a day cannot be ignored. Awareness programs to practice healthy eating habits might help in prevention of obesity and overweight among students. KEY WORDS Breakfast, Exercise, Obesity, Body Mass Index, Students, Medical
- 21 June 2021
- Published by Akshantala Enterprises Private Limited in Journal of Evolution of Medical and Dental Sciences
- Vol. 10 (25) , 1883-1888
Open AccessA Study of Determinants of Obesity - Is Skipping Breakfast Meal a Risk Factor?
BACKGROUND Breakfast is an important meal since it refuels the body after long night fasting. Regular intake of breakfast must have favourable supply of both micronutrients and macronutrients to maintain a body mass index (BMI) in the normal range. Despite its importance, the rate of skipping breakfast is observed to be alarmingly increasing among medical students. Therefore, the present study was undertaken to understand the dietary patterns, and physical activity level, and analyse the association of skipping breakfast with obesity among medical students. METHODS A cross-sectional study was conducted among 174 medical undergraduate students aged between 18 and 23 years in a tertiary care teaching hospital from August 2019 to October 2019. A pretested, semi-structured, validated, self-administered questionnaire was used to assess the profile, physical activity, food consumption pattern, and perception about the importance of breakfast meal. Regression analysis was done. Odds ratio was calculated. RESULTS About 23.6 % and 27 % of the study participants were found to be overweight and obese respectively. Only 51.1 % of study participants were involved in physical activity. 17.2 % of medical students skipped their breakfast regularly and 71.6 % were aware that skipping breakfast would affect work efficacy and span of concentration. Age group of 22 – 23 years (OR: 19.5, 95 % CI; 2.08, 183.70) was significantly associated with obesity. Skipping breakfast (OR, 0.45, 95 % CI: 0.23, 0.90) was not found to be associated with obesity. CONCLUSIONS Our study found that more than one fourth participants were obese and one third were skipping breakfast daily or more than thrice a week. There was no association between obesity and skipping of breakfast meal. However, the importance of breakfast meal in a day cannot be ignored. Awareness programs to practice healthy eating habits might help in prevention of obesity and overweight among students. KEY WORDS Breakfast, Exercise, Obesity, Body Mass Index, Students, Medical
- 9 July 2019
- Published by S. Karger AG in Pediatric Neurosurgery
- Vol. 54 (4) , 237-244
Traumatic Pediatric Extradural Hematoma: An Institutional Study of 228 Patients in Tertiary Care Center
Background: Extradural hematoma (EDH) is one of the most common causes of mortality and morbidity after traumatic brain injury in pediatric patients. Early surgical intervention in these patients produces excellent results. Objective: We reviewed surgical experience at our center, examining and presenting symptomatology and outcome analysis. Materials and Methods: A retrospective study of 228 pediatric patients of EDH from July 2007 to August 2017 was performed. Patients were evaluated in terms of demographic profile, clinical features, pupillary size and reaction, computed tomography findings, operative measures, and several other parameters. Neurological status was assessed using motor component (M) of Glasgow Coma Scale score. Best motor response was considered as a criterion to classify severity of traumatic brain injury and for the assessment of outcome. Results: Most of the patients were in the age group of 13–18 years (n = 122, 53.5%). Majority of them were male (n = 182, 79.8%). The commonest mode of injury was fall from height (n = 116, 50.9%) followed by road traffic accident (n = 92, 40.4%). Most common site of hematoma was frontal region (n = 66, 28.9%) followed by parietal region (n = 54, 23.7%). The volume of hematoma was between 30 and 50 mL in majority of the patients (n = 186, 81.6%), and most of the patients had a motor responses of M5 (n = 88, 38.6%) and M6 (n = 108, 47.4%). The association between hematoma site and volume was not significant (χ2 = 5.910, p = 0.749), whereas statistically significant association was noted between volume of hematoma and motor response (χ2 = 93.468, p ≤ 0.001), volume and age (χ2 = 7.380, p ≤ 0.05), and volume to time between trauma and surgery (χ2 = 8.469, p ≤ 0.05). Maximum mortality was in patients of low motor (M1–M3) response and who were operated 24 h after injury. Conclusion: Mortality in patients of EDH can be significantly reduced with gratifying results if operated early. Best motor response at presentation, pupillary abnormalities, time between injury to surgery, and location of hematoma have been identified as the important factors determining outcome in patients of EDH.
- 9 July 2019
- Published by S. Karger AG in Pediatric Neurosurgery
- Vol. 54 (4) , 237-244
Traumatic Pediatric Extradural Hematoma: An Institutional Study of 228 Patients in Tertiary Care Center
Background: Extradural hematoma (EDH) is one of the most common causes of mortality and morbidity after traumatic brain injury in pediatric patients. Early surgical intervention in these patients produces excellent results. Objective: We reviewed surgical experience at our center, examining and presenting symptomatology and outcome analysis. Materials and Methods: A retrospective study of 228 pediatric patients of EDH from July 2007 to August 2017 was performed. Patients were evaluated in terms of demographic profile, clinical features, pupillary size and reaction, computed tomography findings, operative measures, and several other parameters. Neurological status was assessed using motor component (M) of Glasgow Coma Scale score. Best motor response was considered as a criterion to classify severity of traumatic brain injury and for the assessment of outcome. Results: Most of the patients were in the age group of 13–18 years (n = 122, 53.5%). Majority of them were male (n = 182, 79.8%). The commonest mode of injury was fall from height (n = 116, 50.9%) followed by road traffic accident (n = 92, 40.4%). Most common site of hematoma was frontal region (n = 66, 28.9%) followed by parietal region (n = 54, 23.7%). The volume of hematoma was between 30 and 50 mL in majority of the patients (n = 186, 81.6%), and most of the patients had a motor responses of M5 (n = 88, 38.6%) and M6 (n = 108, 47.4%). The association between hematoma site and volume was not significant (χ2 = 5.910, p = 0.749), whereas statistically significant association was noted between volume of hematoma and motor response (χ2 = 93.468, p ≤ 0.001), volume and age (χ2 = 7.380, p ≤ 0.05), and volume to time between trauma and surgery (χ2 = 8.469, p ≤ 0.05). Maximum mortality was in patients of low motor (M1–M3) response and who were operated 24 h after injury. Conclusion: Mortality in patients of EDH can be significantly reduced with gratifying results if operated early. Best motor response at presentation, pupillary abnormalities, time between injury to surgery, and location of hematoma have been identified as the important factors determining outcome in patients of EDH.